表纸
市场调查报告书

缓激肽B1受体 (B1R) - 开发中产品分析

Bradykinin B1 Receptor (B1R) - Pipeline Review, H1 2019

出版商 Global Markets Direct 商品编码 358701
出版日期 内容资讯 英文 36 Pages
订单完成后即时交付
价格
Back to Top
缓激肽B1受体 (B1R) - 开发中产品分析 Bradykinin B1 Receptor (B1R) - Pipeline Review, H1 2019
出版日期: 2019年03月13日内容资讯: 英文 36 Pages
简介

缓激肽B1受体是藉由BDKRB1遗传基因编码的蛋白偶联受体 (GPCR) 。其配体是病理学状态 (发炎,外伤,烫伤,休克,过敏之类的) 产生的缓激肽。

本报告提供缓激肽B1受体 (B1R)的开发情形调查分析,提供您开发中产品概要,临床实验的各阶段产品概要,主要企业简介,药物简介,开发中产品的最新趋势,最新消息和新闻稿等系统性资讯。

目录

简介

概要

治疗药的开发

  • 开发中的产品:各开发阶段
  • 开发中的产品:各治疗领域
  • 开发中的产品:各适应症

开发中产品的概要

  • 初期阶段的产品

开发中的产品:各企业

开发中的产品:各大学/研究机关

治疗药的评估

  • 单剂/联合治疗别
  • 各作用机制
  • 各给药途径
  • 各分子类型

开发治疗药的企业

  • Axxam SpA
  • Boehringer Ingelheim GmbH
  • Dompe Farmaceutici S.p.A.
  • Grunenthal GmbH

药物简介

暂停的计划

开发中止的产品

最新消息和新闻稿

附录

图表

目录
Product Code: GMDHC0021TDB

Summary:

Global Markets Direct's, 'Bradykinin B1 Receptor (B1R) - Pipeline Review, H1 2016', provides in depth analysis on Bradykinin B1 Receptor (B1R) targeted pipeline therapeutics.

The report provides comprehensive information on the Bradykinin B1 Receptor (B1R) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Bradykinin B1 Receptor (B1R) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Bradykinin B1 Receptor (B1R)
  • The report reviews Bradykinin B1 Receptor (B1R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Bradykinin B1 Receptor (B1R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Bradykinin B1 Receptor (B1R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Bradykinin B1 Receptor (B1R) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Bradykinin B1 Receptor (B1R)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bradykinin B1 Receptor (B1R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bradykinin B1 Receptor (B1R) Overview
  • Therapeutics Development
    • Bradykinin B1 Receptor (B1R) - Products under Development by Stage of Development
    • Bradykinin B1 Receptor (B1R) - Products under Development by Therapy Area
    • Bradykinin B1 Receptor (B1R) - Products under Development by Indication
  • Bradykinin B1 Receptor (B1R) - Pipeline Products Glance
    • Early Stage Products
  • Bradykinin B1 Receptor (B1R) - Products under Development by Companies
  • Bradykinin B1 Receptor (B1R) - Products under Development by Universities/Institutes
  • Bradykinin B1 Receptor (B1R) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Bradykinin B1 Receptor (B1R) - Companies Involved in Therapeutics Development
    • Axxam SpA
    • Boehringer Ingelheim GmbH
    • Dompe Farmaceutici S.p.A.
    • Grunenthal GmbH
  • Bradykinin B1 Receptor (B1R) - Drug Profiles
    • BI-113823 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Antagonize Bradykinin Receptor B1 for Lupus Nephritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize Bradykinin B1 Receptor for Chronic Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize BDKRB1 for Pain and Ophthalmic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize BKB1R for Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Antagonize Bradykinin B1 Receptor for Respiratory Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Bradykinin B1 Receptor (B1R) - Dormant Projects
  • Bradykinin B1 Receptor (B1R) - Discontinued Products
  • Bradykinin B1 Receptor (B1R) - Featured News & Press Releases
    • May 05, 2014: Possible Treatment for Kidney Disease in Lupus Studied at UH
    • Feb 07, 2014: Researchers Exploring Treatment For Lupus-Based Kidney Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Axxam SpA, H1 2016
  • Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Pipeline by Dompe Farmaceutici S.p.A., H1 2016
  • Pipeline by Grunenthal GmbH, H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top